Global Custom Market Research Reports Provider Company

phone

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018

  • Published Date: 10 Jul 2018
  • Number of Pages: 35
  • Category: Pharmaceuticals
  • Country: Global

20%

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018, provides an overview of the Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline landscape.

Non-ulcer dyspepsia is a term used to describe signs and symptoms of indigestion that have no obvious cause. Non-ulcer dyspepsia is also called functional dyspepsia or non-ulcer stomach pain. Signs and symptoms include burning sensation or discomfort in upper abdomen or lower chest, sometimes relieved by food or antacids, bloating, belching and nausea. The predisposing factors include consuming excessive amounts of caffeine or alcohol, smoking and taking certain medications, especially certain over-the-counter pain relievers, such as aspirin and ibuprofen (advil, motrin, others), which can cause stomach problems. Treatment includes medications to reduce acid production, antibiotics and low-dose antidepressants.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Functional (Non Ulcer) Dyspepsia (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Functional (Non Ulcer) Dyspepsia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Functional (Non Ulcer) Dyspepsia (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Functional (Non Ulcer) Dyspepsia (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Functional (Non Ulcer) Dyspepsia (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Functional (Non Ulcer) Dyspepsia (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Functional (Non Ulcer) Dyspepsia (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Functional (Non Ulcer) Dyspepsia (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Functional (Non Ulcer) Dyspepsia - Overview
Functional (Non Ulcer) Dyspepsia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Functional (Non Ulcer) Dyspepsia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Functional (Non Ulcer) Dyspepsia - Companies Involved in Therapeutics Development
Daewoong Pharmaceutical Co Ltd
RaQualia Pharma Inc
Zeria Pharmaceutical Co Ltd
Functional (Non Ulcer) Dyspepsia - Drug Profiles
5-BIOP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acotiamide hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LT-4005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mosapride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naronapride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00000010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00201894 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Functional (Non Ulcer) Dyspepsia - Dormant Projects
Functional (Non Ulcer) Dyspepsia - Discontinued Products
Functional (Non Ulcer) Dyspepsia - Product Development Milestones
Featured News & Press Releases
Mar 25, 2013: Zeria Pharma Receives Approval For Acofide In Japan For Treating Functional Dyspepsia
Feb 29, 2012: RaQualia Pharma Receives MHRA Approval To Initiate First-In-Human Study For 5-HT4 Partial Agonist RQ-00000010
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Functional (Non Ulcer) Dyspepsia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Functional (Non Ulcer) Dyspepsia - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018
Functional (Non Ulcer) Dyspepsia - Pipeline by RaQualia Pharma Inc, H2 2018
Functional (Non Ulcer) Dyspepsia - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2018
Functional (Non Ulcer) Dyspepsia - Dormant Projects, H2 2018
Functional (Non Ulcer) Dyspepsia - Discontinued Products, H2 2018

List Of Figures

List of Figures
Number of Products under Development for Functional (Non Ulcer) Dyspepsia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Top Trends in Healthcare and OTC Products 2018 - The latest trends in: OTC medication; vitamins, minerals, and supplements; functional food and drink; and sports nutrition Top Trends in Healthcare and

View Report

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018, provides an overview

View Report

Report Functional Chewing Gum-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Functional Chewing Gum industry, standing on the readers perspective, delivering detailed market data and

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports